Gonorrhoea treatment failure caused by a <i>Neisseria gonorrhoeae</i> strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.

Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, Morgan M, Newnham R, Golparian D, Unemo M, Crook DW, Peto TE, Hughes G, Cole MJ, Fifer H, Edwards A, Andersson MI. · 2018

Read Gonorrhoea treatment failure caused by a <i>Neisseria gonorrhoeae</i> strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. by Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, Morgan M, Newnham R, Golparian D, Unemo M, Crook DW, Peto TE, Hughes G, Cole MJ, Fifer H, Edwards A, Andersson MI. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6152157.txt.

Introduction

Eyre and co-authors report a case in Eurosurveillance of gonorrhoea that resisted standard treatment in England in February 2018. A man was diagnosed after sex in Thailand with a woman living there. His infection carried resistance to ceftriaxone and high-level resistance to azithromycin, the two main drugs.

First-line treatment with ceftriaxone plus doxycycline failed. A second drug, spectinomycin, also failed. Genome sequencing showed two resistance mechanisms combined in one strain. Its background resembled a commonly circulating strain. The authors warn that urgent action is needed to stop further spread. The case is an early alarm for hard-to-treat gonorrhoea.

Catalog record

CREATOREyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, Morgan M, Newnham R, Golparian D, Unemo M, Crook DW, Peto TE, Hughes G, Cole MJ, Fifer H, Edwards A, Andersson MI.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6152157

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018 By David W Eyre, Nicholas D Sanderson, Emily Lord, Natasha Regisford-Reimmer, Kevin Chau, Leanne Barker, Markus Morgan, Robert Newnham, Daniel Golparian, Magnus Unemo, Derrick W Crook, Tim EA Peto Published in: Eurosurveillance DOI: 10.2807/1560-7917.ES.2018.23.27.1800323 ABSTRACT Abstract We describe a gonorrhoea case with combined high-level azithromycin resistance and ceftriaxone resistance. In February 2018, a heterosexual male was diagnosed with gonorrhoea in the United Kingdom following sexual intercourse with a locally resident female in Thailand and failed treatment with ceftriaxone plus doxycycline and subsequently spectinomycin. Resistance arose from two mechanisms combining for the first time in a genetic background similar to a commonly circulating strain. Urgent action is essential to prevent further spread. Keywords: gonorrhoea; treatment failure; antimicrobial resistance; antimicrobial treatment, whole-genome sequencing Antimicrobial resistance in Neisseria gonorrhoeae is a major concern. Dual therapy with ceftriaxone and azithromycin, the last two mainstream agents to which N. gonorrhoeae remains largely susceptible, is widely recommended internationally [1]. We describe a case of urethral and pharyngeal infection with N. gonorrhoeae with combined high-level azithromycin resistance and ceftriaxone resistance. Previously no such cases have been reported. CASE DESCRIPTION AND MICROBIOLOGY In February 2018, a heterosexual male presented to a sexual health clinic in the United Kingdom (UK) with a 4-day history of urethral discharge and dysuria. He reported having had sexual intercourse 3 days earlier with a regular female partner in the UK. He also reported having had sex with a locally resident female in Thailand in January 2018; he had no history of sexually transmitted infections and no other past medical history. Examination revealed a creamy white urethral discharge, with 3 + pus cells and Gram-negative intracellular diplococci seen under microscopy, leading to a diagnosis of urethral gonorrhoea infection. He was treated with a single dose of intramuscular ceftriaxone 1 g and oral doxycycline 100 mg twice daily for 7 days. A urine nucleic acid amplification test (NAAT) was positive for N. gonorrhoeae and Chlamydia trachomatis negative. N. gonorrhoeae was cultured from a urethral swab. Antimicrobial susceptibility testing was undertaken by M.I.C. Evaluator Strips (Oxoid, Basingstoke, UK), according to the manufacturer’s instructions, with results confirmed using Etest (BioMérieux, Marcy l’Etoile, France) at Public Health England, Colindale, UK and the WHO Collaborating Centre for Gonorrhoea and other STIs, Sweden. European Committee on Antimicrobial Susceptibility Testing resistance breakpoints were used [2]. The minimum inhibitory concentrations (MICs) of nine antimicrobials are given in Table 1 and demonstrate high-level resistance to azithromycin (> 256 mg/L) and resistance to ceftriaxone (0.5 mg/L), as well as tetracycline (32 mg/L) and ciprofloxacin (> 32 mg/L). The patient was recalled and during this visit, 13 days after starting ceftriaxone/doxycycline treatment, his symptoms had resolved and a urine NAAT was negative for N. gonorrhoeae. However, given the previous antibiotic susceptibility profile, he was treated with a single dose of intramuscular spectinomycin (2 g). At a follow-up appointment, 20 days later, a urine NAAT was negative but a pharyngeal swab (omitted accidentally at the prior visits; the patient was asymptomatic at this site) was culture-positive for N. gonorrhoeae thus fulfilling international criteria for a verified treatment failure [3] as no further contact was reported with the Thai female following initial treatment. The same MICs were obtained from both cultured isolates from the case. Following this, the patient was treated with ertapenem (1 g) intravenously for 3 days. Subsequent NAAT and culture of urethral and pharyngeal swabs a further 21 days later were negative. The patient’s regular UK partner had negative vaginal and pharyngeal swab NAATs. We were unable to contact the patient’s partner from Thailand who the patient had initially met via a dating website. [Table: Antimicrobial minimum inhibitory concentrations, Neisseria gonorrhoeae case imported from Thailand to England, February 2018] ANTIMICROBIAL RESISTANCE DETERMINANTS AND SEQUENCE ANALYSIS By combining short-read (Illumina, San Diego, California, United States of America) and long-read (Oxford Nanopore Technologies, Oxford, UK) sequence data a complete hybrid 2.17Mb assembly for each isolate was determined, these have been deposited, together with raw sequence data, in the European Nucleotide Archive (PRJEB26560; see supplement for details). Mapping sequence reads to one of these novel reference genomes as previously described [4], the sequences of the pre-treatment urethral (G97687) and the post-initial treatment pharyngeal (G7944) isolates from the case were indistinguishable i.e. they were consistent with acquisition from the same source at both anatomical sites. The isolates had a novel N. gonorrhoeae multi-antigen sequence typing (NG-MAST) sequence type (ST), ST16848 determined in silico [4], and were assigned MLST 12039. Antimicrobial resistance determinants were identified from the sequencing data as described previously using a combination of de novo assembly and mapping-based approaches [5]. The isolates from the case included an identical mosaic penA allele to that previously identified in the ceftriaxone-resistant FC428 strain isolated in Japan in 2015, which also had a ceftriaxone MIC of 0.5 mg/L [6]. This mosaic penA allele contains two key ceftriaxone resistance mutations, A311V and T483S, but not the T316P mutation found in the more resistant H041 strain [7]. The isolates also had the A2059G mutation in all four 23S rRNA genes – the most commonly occurring mutation responsible for high-level azithromycin resistance [8]. Additional antimicrobial resistance determinants are summarised in Table 2. The isolate had a N. gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) type of 996. [Table: Antimicrobial resistance determinants present in isolates, Neisseria gonorrhoeae case imported from Thailand to England, February 2018] Based on reference-based mapping and correcting for recombination [4], previously sequenced ceftriaxone-resistant N. gonorrhoeae isolates, including the FC428 sharing the same penA allele, differed from our case by > 1,500 single nucleotide polymorphisms (SNPs) (Figure 1). [Figure: Genetic relatedness with previous ceftriaxone resistant isolates of Neisseria gonorrhoeae case imported from Thailand to England, February 2018] We compared our isolates’ sequences to all publicly available whole-genome sequenced N. gonorrhoeae isolates. There were 7,812 sequences available for comparison, including European and North American surveillance samples and samples from a global collection. Using a rapid k-mer based search (see supplement for details), we identified the 98 most closely related genomes to the two sequences identified in our case to determine a maximum-likelihood phylogeny (Figure 2). The phylogeny contains two deep clades, the top clade contains the sequences from our case, which is predominantly from NG-MAST ST4995 and closely-related STs (collectively known as genogroup G4995); our case differs from G4995 by approximately 400 SNPs. The most closely related genomes were within 45 SNPs and were obtained in China (isolation dates unavailable) with additional genomes within 54 and 71 SNPs from the UK (2014) and Japan (2015), respectively. N. gonorrhoeae evolves at 3.6 SNPs per genome per year [4] meaning that the most recent common ancestor of these strains is likely to be from several years earlier. These related sequences each contained four copies of the 23S rRNA A2059G mutation conferring high-level azithromycin resistance; however, all contained the ceftriaxone-susceptible penA II allele. No other sequence in the tree contained any of the three penA key mutations associated with ceftriaxone resistance i.e. A311V, T316P and T483S. [Figure: Phylogeny of the most closely related existing Neisseria gonorrhoeae genome sequences to the imported Neisseria gonorrhoeae case from Thailand

Read the complete text